Clinical Pharmacokinetics

, Volume 56, Issue 6, pp 661–669

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir

  • Matt S. Anderson
  • Sauzanne Khalilieh
  • Ka Lai Yee
  • Rachael Liu
  • Li Fan
  • Matthew L. Rizk
  • Vedangi Shah
  • Azra Hussaini
  • Ivy Song
  • Lisa L. Ross
  • Joan R. Butterton
Original Research Article



Doravirine, a non-nucleoside reverse-transcriptase inhibitor in development for the treatment of patients with human immunodeficiency virus-1 infection, has potential to be used concomitantly in antiretroviral therapy with dolutegravir, an integrase strand transfer inhibitor. The pharmacokinetic interactions between these drugs were therefore assessed.


Oral formulations of doravirine and dolutegravir were dosed both individually and concomitantly once daily in healthy adults. Twelve subjects (six were male), 23–42 years of age, were enrolled and 11 completed this phase I, open-label, three-period, fixed-sequence study per protocol; one subject was discontinued for a positive cotinine test at admission to period 2. In period 1, dolutegravir 50 mg was administered for 7 days. After a 7-day washout, doravirine 200 mg was dosed for 7 days in period 2, followed (without washout) by both doravirine and dolutegravir simultaneously for 7 days in period 3. Plasma samples were taken to determine dolutegravir and doravirine concentrations.


The steady-state concentration 24 h post-dose (C24) of dolutegravir was not substantially altered by co-administration of doravirine multiple doses; area under the plasma concentration–time curve from dosing to 24 h post-dose (AUC0–24), maximum concentration (Cmax), and C24 geometric mean ratios were 1.36, 1.43, and 1.27, respectively. The pharmacokinetics of doravirine was not affected by multiple doses of dolutegravir (geometric mean ratios: 1.00, 0.98, and 1.06 for AUC0–24, C24, and Cmax, respectively). Both drugs were generally well tolerated.


The results of this study demonstrate that concomitant administration of doravirine and dolutegravir in healthy subjects causes no clinically significant alteration in the pharmacokinetic and safety profiles of the two drugs, thereby supporting further evaluation of co-administration of these agents for human immunodeficiency virus-1 treatment.


  1. 1.
    DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Accessed 2016 March 25.
  2. 2.
    Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5:563–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Bedimo R, Maalouf NM, Zhang S, et al. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–31.CrossRefPubMedGoogle Scholar
  4. 4.
    Montessori V, Press N, Harris M, et al. Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004;170:229–38.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Nolan D, Mallal S. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther. 2004;9:849–63.PubMedGoogle Scholar
  6. 6.
    Margolis AM, Heverling H, Pham PA, et al. A review of the toxicity of HIV medications. J Med Toxicol. 2014;10:26–39.CrossRefPubMedGoogle Scholar
  7. 7.
    Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr. 2007;45(Suppl 1):S14–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Aldir I, Horta A, Serrado M. Single-tablet regimens in HIV: does it really make a difference? Curr Med Res Opin. 2014;30:89–97.CrossRefPubMedGoogle Scholar
  9. 9.
    Fernandez-Montero JV, Vispo E, Soriano V. Emerging antiretroviral drugs. Expert Opin Pharmacother. 2014;15:211–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Fantauzzi A, Mezzaroma I. Dolutegravir: clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis. 2014;5:164–77.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Keeshin SW, Feinberg J. Evaluation of dolutegravir safety for the treatment of HIV-1. Expert Opin Drug Saf. 2015;14:141–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Eron JJ, Clotet B, Durant J, et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis. 2013;207:740–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Castagna A, Maggiolo F, Penco G, et al. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis. 2014;210:354–62.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Canducci F, Ceresola ER, Boeri E, et al. Cross-resistance profile of the novel integrase inhibitor dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis. 2011;204:1811–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20:397–405.CrossRefPubMedGoogle Scholar
  16. 16.
    Gatell JM, Raffi F, Plettenberg A, et al. Efficacy and safety of doravirine 100 mg QD vs efavirenz 600 mg QD with TDF/FTC in ART-naive HIV-infected patients: week 24 results. 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention,  July 18-22, 2015, Vancouver, Canada. TUAB0104. Accessed 22 Sept 2016.
  17. 17.
    Feng M, Wang D, Grobler JA, et al. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways. Antimicrob Agents Chemother. 2015;59:590–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Gatell JM, Morales-Ramirez JO, Hagins DP, et al. Forty-eight-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-naive HIV-positive patients. J Int AIDS Soc. 2014;17(4 Suppl 3):19532.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Kandel CE, Walmsley SL. Dolutegravir: a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Des Develop Ther. 2015;9:3547–55.CrossRefGoogle Scholar
  20. 20.
    Sanchez RI, Fillgrove K, Hafey M, et al. In vitro evaluation of doravirine potential for pharmacokinetic drug interactions. Accessed 2016 March 25.
  21. 21.
    Schürmann D, Sobotha C, Gilmartin J, et al. A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals. AIDS. 2016;30:57–63.PubMedGoogle Scholar
  22. 22.
    Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics. 1997;53:983–97.CrossRefPubMedGoogle Scholar
  23. 23.
    Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2:760–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Yee KL, Chatterjee M, Dockendorf M, et al. Pharmacokinetics (PK) of doravirine and exposure-response analysis: efficacy and safety implications. In: 54th interscience conference on antimicrobial agents and chemotherapy (ICAAC), 5–9 Sept 2014, Washington, DC. Accessed 28 Sept 2016.
  25. 25.
    Xu Y, Li YF, Zhang D, et al. Characterizing class-specific exposure-viral load suppression response of HIV antiretrovirals using a model-based meta-analysis. Clin Transl Sci. 2016;9(4):192–200.CrossRefPubMedGoogle Scholar
  26. 26.
    TIVICAY (dolutegravir) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline. 2013. Accessed 25 Jan 2016.
  27. 27.
    Song I, Borland J, Chen S, et al. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother. 2012;56:1627–9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Reese MJ, Savina PM, Generaux GT, et al. In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. Drug Metab Dispos. 2013;41:353–61.CrossRefPubMedGoogle Scholar
  29. 29.
    Song I, Chen S, Piscitelli SC, Min S. Pharmacokinetics (PK) and PK-pharmacodynamic (PD) relationship of dolutegravir (DTG) in integrase inhibitor (INI)-naïve subjects. In: 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 10-13, 2013, Denver, CO. Accessed 22 Sept 2016.
  30. 30.
    Clotet B, Feinberg J, van LJ, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–31.CrossRefPubMedGoogle Scholar
  31. 31.
    Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–18.CrossRefPubMedGoogle Scholar
  32. 32.
    Song I, Borland J, Min S, et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother. 2011;55:3517–21.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Dailly E, Allavena C, Gregoire M, et al. Influence of nevirapine administration on the pharmacokinetics of dolutegravir in patients infected with HIV-1. J Antimicrob Chemother. 2015;70:3307–10.PubMedGoogle Scholar
  34. 34.
    Cottrell ML, Hadzic T, Kashuba AD. Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir. Clin Pharmacokinet. 2013;52:981–94.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Min S, Song I, Borland J, et al. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010;54:254–8.CrossRefPubMedGoogle Scholar
  36. 36.
    van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis. 2012;12:111–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Matt S. Anderson
    • 1
  • Sauzanne Khalilieh
    • 1
  • Ka Lai Yee
    • 1
  • Rachael Liu
    • 1
  • Li Fan
    • 1
  • Matthew L. Rizk
    • 1
  • Vedangi Shah
    • 1
  • Azra Hussaini
    • 2
  • Ivy Song
    • 3
  • Lisa L. Ross
    • 4
  • Joan R. Butterton
    • 1
  1. 1.Merck & Co., Inc.KenilworthUSA
  2. 2.PAREXELBaltimoreUSA
  3. 3.GlaxoSmithKlineResearch Triangle ParkUSA
  4. 4.ViiV HealthcareResearch Triangle ParkUSA

Personalised recommendations